Celebrating the Newest President’s Engagement, Innovation, and Sustainability Prize Winners

by Lauren Hertzler

The 2022 cohort of PEP, PIP, and PSP winners smile for a photo with Interim President Wendell Pritchett and Interim Provost Beth Winkelstein.

Last week, on a sunny spring day, the 2022 President’s Engagement, Innovation, and Sustainability Prize winners were recognized at a special luncheon, a momentous occasion that hasn’t taken place in-person since 2019. The 12 Prize recipients and their advisers, as well as past Prize winners and Penn leadership, joined together at the University Meeting and Guest House for a meal, good conversation, and celebration.

To the group, as well as family members tuning in through Zoom, Interim President Wendell Pritchett described this year’s winners as exemplifying creativity and leadership. “They epitomize why these prizes are central to the vision we share for Penn,” he said, before distributing handcrafted certificates to each of the six teams.

Eli Moraru, who earned one of the inaugural President’s Sustainability Prizes for his nonprofit The Community Grocer, said the event was uplifting for two main reasons: The first being that he got to network with his fellow PEP/PIP/PSP cohort, and the second being his connection with past Prize winners.

“It’s a real community,” Moraru said, sharing, as an example, how Christina Miranda from Be Body Positive Philly—a winner in the 2021 cohort—approached him expressing her interest in serving as a resource to his team in any way possible.

“It’s just one more reason showcasing how we aren’t alone in this,” Moraru said.

Chosen from an applicant pool of 71 people, the two other President’s Sustainability Prize-winning teams include Saif Khawaja for Shinkei Systems and Sarah Beth Gleeson, Shoshana Weintraub, and Julia Yan for EcoSPIN. Earning a President’s Innovation Prize, which was founded in 2016, is William Kohler Danon and Lukas Achilles Yancopoulos for Grapevine. In 2015, the very first President’s Engagement Prizes were announced. This year, Penn awarded this honor to two teams: Seungkwon Son, Max Strickberger, and Sam Strickberger for College Green Ventures and Manoj Simha and Rowana Miller from Cosmic Writers. Each team receives $100,000 to help get their projects off the ground, plus a $50,000 living stipend post-graduation per person.

Continue reading at Penn Today.

FDA Approves Penn Pioneered CAR T Cell Therapy for Third Indication

The U.S. Food and Drug Administration has expanded its approval for Kymriah, a personalized cellular therapy developed at the Abramson Cancer Center, this time for the treatment of adults with relapsed/refractory follicular lymphoma who have received at least two lines of systemic therapy. “Patients with follicular lymphoma who relapse or don’t respond to treatment have a poor prognosis and may face a series of treatment options without a meaningful, lasting response,” said Stephen J. Schuster, the Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma in the Division of Hematology Oncology. It’s the third FDA approval for the “living drug,” which was the first of its kind to be approved, in 2017, and remains the only CAR T cell therapy approved for both adult and pediatric patients.

“In just over a decade, we have moved from treating the very first patients with CAR T cell therapy and seeing them live healthy lives beyond cancer to having three FDA-approved uses of these living drugs which have helped thousands of patients across the globe,” said Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in Penn’s Perelman School of Medicine and director of the Center for Cellular Immunotherapies in the Abramson Cancer Center and director of the Parker Institute for Cancer Immunotherapy at Penn. “Today’s news is new fuel for our work to define the future of cell therapy and set new standards in harnessing the immune system to treat cancer.”

Research from June, a member of the Penn Bioengineering Graduate Group, led to the initial FDA approval for the CAR T therapy (sold by Novartis as Kymriah) for treating acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

Read the full announcement in Penn Medicine News.

Center for Engineering Mechanobiology 2.0: Developing ‘Mechanointelligence’

by Evan Lerner

The dynamics governing mechanointelligence vary greatly along time- and length-scales, so detailed models of individual cells and their components are necessary to connect the effects of their physical environments to the downstream effects those forces have on biological processes.

The National Science Foundation’s Science and Technology Center (STC) program is its flagship funding mechanism for organizing interdisciplinary research on cutting-edge topics. Penn’s Center for Engineering MechanoBiology (CEMB) is one of the 18 active STCs, bringing together dozens of researchers from Penn Engineering and the Perelman School of Medicine, as well as others spread across campus and at partner institutions around the world.

With its NSF funding now renewed for another five years, the Center is entering into a new phase of its mission, centered on the nascent concept of “mechanointelligence.”

Mechanobiology is the study of the physical forces that govern the behavior of cells and their communication with their neighbors. Mechanointelligence adds another layer of complexity, attempting to understand the forces that allow cells to sense, remember and adapt to their environments.

Ultimately, harnessing these forces would allow researchers to help multicellular organisms — plants, animals and humans — better adapt to their environments as well.

“Mechanointelligence is a key element of a cell’s ability to survive and reproduce,” says CEMB Director and Eduardo D. Glandt President’s Distinguished Professor Vivek Shenoy. “Just like with complex organisms, a cell’s ‘fitness’ depends on its environment, and adapting means rewiring how its genes are expressed.”

Read the full story in Penn Engineering Today.

Vivek Shenoy is Eduardo D. Glandt President’s Distinguished Professor in Materials Science and Engineering, Bioengineering and Mechanical Engineering and Applied Mechanics.

César de la Fuente Receives 2022 RSEQ Young Investigator Award

César de la Fuente, PhD

César de la Fuente, Presidential Assistant Professor in Psychiatry, Bioengineering, Microbiology, and in Chemical and Biomolecular Engineering has been honored with a 2022 Young Investigator Award by the Royal Spanish Society of Chemistry (RSEQ) for his pioneering research efforts to combine the power of machines and biology to help prevent, detect, and treat infectious diseases.

Read the RSEQ’s announcement here.

This story originally appeared in Penn Medicine News’s Awards & Accolades post for April 2022.